Pharmacogenomics in 2023: Big Studies, Big Results, Big Implications, Big Responsibilities
-
Chair(s):
Andrew Somogyi,
Professor in Clinical and Experimental Pharmacology,University of Adelaide, Adelaide, AustraliaAnn Daly,
Professor of Pharmacogenomics,Newcastle University, Newcastle, United Kingdom -
Session description:
Translating pharmacogenomic sequencing data into drug response predictions - how to interpret variants of unknown significance
Associate Professor Volker Lauschke
Director of the Biofabrication and Tissue Engineering Facility, Karolinska Institute, Stockholm andDr Margarete Fisher-Bosch
Deputy Head, Institute of Clinical Pharmacology, Stuttgart, GermanyWhat have we learnt and what will we learn from the UBIQUITIOUS Pharmacogenomics Consortium
Dr Erika Cecchin
Senior Researcher, Experimental and Clinical Pharmacology Unit, National Cancer Institute, Aviano, ItalyOral communication speaker - to be confirmed in 2023.
Predicting and improving response to medicines: bringing lessons learnt from VUMC to the All of US Research Program
Professor Sara van Driest
Director of Paediatrics, All of Us Research Program, National Institutes of Health, The United States of AmericaStatistical genetics- and machine learning-based approaches to better understand drug safety
Professor Masaru Koido
Yokohama City University, JapanSponsored by:
Speakers
-
Dr Erika CecchinSenior Researcher, Experimental and Clinical Pharmacology Unit, National Cancer Institute, Aviano, Italy
-
Dr Margarete Fisher-BoschDeputy Head, Institute of Clinical Pharmacology, Stuttgart, Germany
-
Professor Masaru KoidoYokohama City University, Yokohama, Japan
-
Professor Sara van DriestDirector of Paediatrics, All of Us Research Program, National Institutes of Health, United States of America
-
Professor Volker LauschkeDirector of the Biofabrication and Tissue Engineering Facility, Karolinska Institute, Sweden
Leave A Comment